Toggle menu

BRAINED Study

Start date:
April 2018
End date:
August 2020
Co-ordinated by:
Neurosurgery Department, Western General Hospital, Edinburgh
Main trial site:
RIE & Western General Hospital, Edinburgh

 

Blood samples will be assessed using infrared spectroscopy as part of a project looking at tumour biomarkers to ascertain whether people most at risk of having a brain tumour can be correctly identified.

This is a tissue governance project aiming to recruit 600 participants in order to inform a larger trial.

Chief Investigator

Mr Paul Brennan

Consultant Neurosurgeon

Local PI

Dr Matt Reed

Director of EMERGE, Consultant, NRS Career Research Fellow & Honorary Reader in Emergency Medicine

Research Team

Rachel O'Brien

Lead Research Nurse

Clare Moceivei

Research Nurse- Bank Staff

Allan MacRaild

Stroke Lead Research Nurse

Jessica Teasdale

Senior Research Nurse - Stroke/Neurosurgery

Michelle Curtin

Senior Research Nurse - Stroke/Neurosurgery

More EMERGE Trials

ETNA: Edinburgh Transient and Neurological attack: A Cohort Study

Patients frequently present with minor neurological symptoms where a diagnosis of transient ischaemic attack (TIA) or minor stroke is difficult to make positively or to exclude reasonably. For these patients, clinicians are uncertain whether they should: (a) reassure most patients that their symptoms are benign; (b) treat most patients with antiplatelet or other vascular prevention; or (c) stratify stroke risk further using clinical features or brain imaging.
This is important because clinical diagnosis is difficult. Mis-diagnosis is not infrequent and leads to harm from preventable recurrent stroke and costs to health systems from extra care and legal liabilities.
All ETNA participants will receive an MRI scan and the study aims to establish the feasibility and methods for a larger study of diagnostic utility of MR brain imaging and estimate the effects of MRI on clinician decision making.
This study has been recruiting in the Emergency Dept, inpatient wards and TIA clinics since August 2018. We aim to recruit 270 participants and have almost reached our target!

Read more

ETNA

Identification and characterization of the clinical toxicology of novel psychoactive substances (NPS) by laboratory analysis of biological samples from recreational drug users.

Read more

IONA Study

Identification of Novel Psychoactive Substances (IONA)

Diagnostics devices play an important part in the clinical assessment of a patient’s health and treatment. The purpose of the study is the evaluation of a new diagnostic platform developed by LumiraDx. The evaluation is focused around various biomarkers useful in the emergency settings.

Read more

NOVEL Study

Collection of venous and capillary blood samples for the evaluation of new diagnostic devices for cardiovascular conditions